Drug Discovery World

APRIL 6, 2023

Programme highlights The topic tracks include everything from clinical trials, drug development, immunology and bioinformatics, to global health, survivorship, prevention and tumour biology, to name just a few.

Small Molecule 130

Small Molecule Targeted Protein Degradation Clinical Trials Engineering 130

Drug Discovery World

JULY 11, 2023

While the potential for better insights has grown, acquiring powerful tools that can harness that data, and turn it into useful, actionable information, has increasingly become one of the most important aspects of life science research. Advances in quantum computing are also showing early promise for increasingly complex data analyses.

Science 100

Science Drugs FDA Engineering 100

Agency IQ

OCTOBER 12, 2023

Leaders at FDA share highlights and updates for drugs and biologics at RAPS Convergence Top officials from FDA’s Centers for drugs and biologics—including Center for Biologics Evaluation and Research (CBER) Director Peter Marks—provided high-level updates at RAPS Convergence 2023 this week. Featuring previous research by Alec Gaffney.

FDA 40

FDA Clinical Trials International Drugs 40

Nvidia Developer: Drug Discovery

DECEMBER 19, 2023

The applications of artificial intelligence for enzyme generation is an exciting field of research with direct applications in the life sciences. Improved methods for functional annotation are a vital component in enzyme research, enabling the identification and characterization of the functions of newly discovered enzymes.

Science 131

Science Small Molecule Bioinformatics Research 131

Broad Institute

JULY 10, 2023

Thanks in part to her research, more geneticists are now studying a wider diversity of people and accounting for genetic ancestry in their analyses. Through this work, Martin is showing how a methodical, data-driven kind of social justice can help improve equity in scientific research and lead to better science.

Bioinformatics 98

Bioinformatics Disease Medical Schools Research 98

Drug Discovery World

NOVEMBER 15, 2022

Even as methods in DNA synthesis continue to advance, scientists’ reliance on third-party companies for synthesising DNA creates a bottleneck, impeding research timelines. . “If This process can be drawn-out, expensive, and time and resource-intensive, often slowing down the momentum of a research study. .

DNA 246

DNA Engineering Drugs Vaccine 246